Showing results (191-200 of 301) with videos related to

Sort By:
Pageof 31
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 8, 2014
[Long-term efficacy of chemotherapy for unresectable gastric cancer with multiple bone metastases-a case report]Yutaka Kimura, Tomono Kawase, Ryohei Kawabata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2010
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)S Ohno, Y Rai, H Iwata, et al.
Influenza and Other Respiratory Viruses|April 4, 2017
Estimates of influenza and respiratory syncytial virus incidences with fraction modeling approach in Baguio City, the Philippines, 2012-2014Taro Kamigaki, Portia P Aldey, Edelwisa S Mercado, et al.
European Heart Journal|April 6, 2005
Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosisShinji Ishimaru, Ichizo Tsujino, Toshiki Takei, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 8, 2022
[Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey]Katsumasa Tsurushima, Yukiko Yanagishita, Naoki Ogawa, et al.
Anticancer Research|June 30, 2016
Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer CellsKeiko Naitoh, Takashi Kamigaki, Eriko Matsuda, et al.
Neurochemistry International|January 24, 2016
The Toll-like receptor 4-activated neuroprotective microglia subpopulation survives via granulocyte macrophage colony-stimulating factor and JAK2/STAT5 signalingMayumi Kamigaki, Izumi Hide, Yuhki Yanase, et al.
Breast Disease|August 23, 2021
Relationship between endocrine resistance and the periods of adjuvant endocrine treatment for hormone receptor-positive, HER2-negative breast cancerJun Yamamura, Yukiko Miyamura, Shunji Kamigaki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 16, 2012
[Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool]Chiya Oshiro, Shunji Kamigaki, Yukio Nakamura, et al.
The Lancet. Oncology|January 24, 2012
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trialNorikazu Masuda, Yasuaki Sagara, Takayuki Kinoshita, et al.
Pageof 31